It targets a new form of the toxic beta-amyloid protein in the brain
Chicago – Reuters
Posted on: July 16, 2023: 12:35 PM GST Last updated: July 16, 2023: 01:36 PM GST
Acumen Pharmaceuticals said on Sunday that an experimental Alzheimer’s drug developed by the company has passed preliminary safety testing and will move into larger trials.
The drug targets a new form of the toxic beta-amyloid protein in the brain.
The company said the drug, ACI 193, was well received in its first trial in patients.
The company presented the results of the study, which was conducted on a random sample of 62 patients with early symptoms of Alzheimer’s disease at the International Conference of the Alzheimer’s Association in Amsterdam.
The study included a comparison between a group of participants who were given the drug with another group who was given a placebo.
Acumen’s chief medical officer, Dr. Eric Simers, said in an interview that the new drug developed by the company targets and binds to oligomers of beta-amyloid, a toxic, soluble version of the amyloid protein that forms brain plaques associated with the disease.
In the “Acumen” trial, the company said that those who get higher doses of the new drug have reduced rates of amyloid plaques after a period ranging between six and 12 weeks, indicating that the drug may be given to patients by intravenous injection once a month.
2023-07-16 08:35:00
#Alzheimers #drug #passes #initial #safety #test
